SBFM - Sunshine Biopharma Inc. Stock Price, Fair Value and News

0.84USD0.00 (0.00%)Delayed

Market Summary

USD0.840.00

Delayed

0.00%

SBFM Stock Price

View Fullscreen

SBFM RSI Chart

SBFM Valuation

Market Cap

835.4K

Price/Earnings (Trailing)

-0.19

Price/Sales (Trailing)

0.03

EV/EBITDA

4.04

Price/Free Cashflow

-0.09

SBFM Price/Sales (Trailing)

SBFM Profitability

Operating Margin

34.61%

EBT Margin

-17.06%

Return on Equity

-21.25%

Return on Assets

-16.48%

Free Cashflow Yield

-1.1K%

SBFM Fundamentals

SBFM Revenue

Revenue (TTM)

24.1M

Rev. Growth (Yr)

94.94%

Rev. Growth (Qtr)

28.91%

SBFM Earnings

Earnings (TTM)

-4.5M

Earnings Growth (Yr)

94.68%

Earnings Growth (Qtr)

-91.87%

Breaking Down SBFM Revenue

Last 7 days

-11.6%

Last 30 days

-92.3%

Last 90 days

-96.5%

Trailing 12 Months

-98.4%

How does SBFM drawdown profile look like?

SBFM Financial Health

Current Ratio

4.48

SBFM Investor Care

Shares Dilution (1Y)

349.20%

Diluted EPS (TTM)

-19

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	9.1M	14.5M	20.4M	24.1M
2022	327.5K	424.9K	507.3K	4.3M
2021	54.8K	87.3K	130.8K	212.0K
2020	97.2K	111.2K	101.7K	71.4K
2019	158.5K	108.8K	114.7K	106.1K
2018	115.5K	149.3K	183.2K	217.1K
2017	73.2K	76.0K	78.8K	81.6K
2016	150.1K	355.4K	329.7K	70.4K
2015	265.8K	146.4K	152.4K	164.8K
2014	184.1K	278.5K	270.7K	268.3K
2013	0	167.5K	172.9K	157.0K
2012	37.8K	48.5K	92.7K	101.9K
2011	57.1K	48.9K	40.7K	32.5K
2010	0	0	0	65.3K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Sunshine Biopharma Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 04, 2024	slilaty steve n.	bought	10,000	0.1	100,000	chief executive officer
Feb 08, 2024	slilaty steve n.	bought	2,000	0.1	20,000	chief executive officer
Nov 30, 2022	sebaaly camille	bought	22,905	0.7635	30,000	cfo/secretary
Jun 03, 2022	sebaaly camille	bought	30,500	1.22	25,000	cfo/secretary
Feb 18, 2022	slilaty steve n.	back to issuer	-99,000	0.1	-990,000	chief executive officer
Jan 06, 2021	sebaaly camille	acquired	20,000	0.001	20,000,000	cfo/secretary
Jan 06, 2021	merzouki abderrazzak	acquired	20,000	0.001	20,000,000	chief operating officer
Jan 06, 2021	slilaty steve n.	acquired	20,000	0.001	20,000,000	chief executive officer
Jun 17, 2020	slilaty steve n.	acquired	50,000	0.1	500,000	chief executive officer
Dec 31, 2019	sebaaly camille	sold	-323	0.001	-323,673	cfo/secretary

Which funds bought or sold SBFM recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 09, 2024	Rise Advisors, LLC	unchanged	-	-4.00	1.00	-%
Feb 26, 2024	Virtu Financial LLC	new	-	6,000	6,000	-%
Feb 15, 2024	Main Street Group, LTD	new	-	60.00	60.00	-%
Feb 14, 2024	CITADEL ADVISORS LLC	new	-	50,297	50,297	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	added	100	8.00	30.00	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	new	-	2,710	2,710	-%
Feb 14, 2024	CLEAR STREET LLC	reduced	-4.6	-	-	-%
Feb 14, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	unchanged	-	-11,301	77,676	-%

Are Funds Buying or Selling SBFM?

Are funds buying SBFM calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SBFM

No. of Funds

Unveiling Sunshine Biopharma Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 23, 2024	l1 capital global opportunities master fund, ltd.	5.3%	5,285,714	SC 13G
Feb 21, 2024	altium capital management lp	9.99%	3,727,984	SC 13G
Feb 14, 2024	armistice capital, llc	7.60%	2,130,000	SC 13G
Nov 02, 2022	chamoun malek	16.4%	3,700,000	SC 13G
Jul 29, 2021	beathard robert king 3rd	8.07%	39,231,743	SC 13G

Recent SEC filings of Sunshine Biopharma Inc.

View All Filings

Date Filed	Form Type	Document
Apr 23, 2024	8-K	Current Report
Apr 01, 2024	8-K	Current Report
Mar 28, 2024	10-K	Annual Report
Mar 15, 2024	DEF 14C	DEF 14C
Mar 06, 2024	8-K	Current Report
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	DEF 14C	DEF 14C
Mar 05, 2024	PRE 14C	PRE 14C
Mar 01, 2024	8-K	Current Report
Feb 23, 2024	SC 13G	Major Ownership Report

Peers (Alternatives to Sunshine Biopharma Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	359.2B	85.6B	-3.24%	-7.94%	9.34	4.19	5.68%	202.39%
MRK	323.0B	61.4B	-1.84%	8.64%	140.05	5.26	6.11%	-82.30%
AMGN	166.9B	29.5B	13.40%	34.20%	44.36	5.65	12.76%	-52.47%
PFE	157.1B	46.5B	2.20%	-27.23%	-113.14	3.37	42.59%	-114.62%
GILD	80.7B	27.1B	-8.62%	-17.50%	14.25	2.98	-0.60%	23.36%
TEVA	15.6B	15.8B	-0.99%	61.25%	-27.18	0.99	6.17%	76.47%
MID-CAP
PRGO	4.4B	4.7B	5.70%	-11.21%	-349.99	0.95	4.58%	90.97%
ALKS	4.1B	1.7B	-8.55%	-16.13%	9.38	2.36	54.01%	364.56%
BHC	2.9B	9.0B	-22.11%	32.77%	-6.3	0.32	10.01%	-27.45%
AMPH	2.0B	644.4M	1.22%	16.11%	14.84	3.17	29.14%	50.51%
SMALL-CAP
TLRY	1.6B	743.2M	-26.67%	-17.06%	-4.6	2.18	24.65%	80.36%
TXMD	22.0M	1.3M	-14.35%	-52.84%	-2.14	16.92	-98.14%	-109.18%
ACRX	17.1M	-	-	62.93%	-0.93	0.22	2882.68%	-138.52%
AGRX	2.5M	19.6M	35.71%	-93.63%	-0.17	0.13	80.00%	43.08%
ACOR	1.1M	117.6M	-94.70%	-92.62%	0	0.01	-0.79%	-283.60%

Sunshine Biopharma Inc. News

Latest updates

Sunshine Biopharma Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	28.9%	7,680,201	5,957,668	5,560,865	4,894,053	3,939,843	132,808	150,307	122,645	101,589	50,376	52,874	7,117	20,440	6,895	20,351	23,724	50,740	16,402	6,313	32,656	59,316
Cost Of Revenue	28.9%	5,112,155	3,967,412	3,608,118	3,065,931	2,448,717	65,783	74,683	59,845	61,289	19,506	18,515	18,520	10,463	6,340	5,161	3,883	4,185	5,293	1,460	112	-50,409
Gross Profit	29.0%	2,568,046	1,990,256	1,952,747	1,828,122	1,491,126	67,025	75,624	62,800	23,829	30,870	34,359	21,538	17,550	10,810	9,984	7,219	6,371	2,033	1,573	94.00	4,826
S&GA Expenses	35.6%	3,755,267	2,769,730	2,942,370	3,657,103	24,854,736	1,785,005	771,420	1,286,164	303,460	527,129	422,957	1,297,184	360,868	78,098	138,553	44,918	256,961	204,673	67,770	122,303	140,810
R&D Expenses	243.0%	816,328	238,012	368,565	432,925	41,763	362,500	45,943	361,652	91,198	222,465	191,760	166,786	1,728	-	-	-	-	15,204	-	-	12,800
EBITDA Margin	87.6%	-0.16	-1.28	-1.86	-2.94	-6.09	-24.40	-29.01	-37.05	-57.06	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-21.8%	30,110	38,527	27,596	41,075	26,546	2.00	-	12,864	36,629	46,849	195,630	49,711	105,436	22,094	24,219	16,356	23,415	27,847	18,342	46,297	25,511
Income Taxes	437.9%	220,267	40,952	87,677	46,270	233,304	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-68.7%	-1,029,757	-610,530	-814,431	-1,656,160	-23,279,011	-1,457,019	-538,872	-1,236,234	-	-	-	-	-	-	-	-	-	-	-	-	-
EBT Margin	86.8%	-0.17	-1.30	-1.87	-2.95	-6.10	-24.51	-29.27	-37.98	-58.67	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-91.9%	-1,250,024	-651,482	-902,108	-1,702,430	-23,512,315	-1,457,019	-538,872	-1,236,234	667,116	-4,039,383	-2,879,054	-6,185,126	-1,083,793	-698,595	-907,444	-94,259	-396,618	-350,241	-710,890	-202,542	-338,655
Net Income Margin	85.8%	-0.19	-1.32	-1.90	-2.98	-6.15	-5.06	-12.11	-22.86	-58.67	-108	-124	-161	-	-	-	-	-	-	-	-	-
Free Cashflow	-394.2%	-2,307,313	-466,923	-3,972,022	-2,044,088	-2,440,594	-1,123,736	-573,802	-1,304,208	-312,113	-601,199	-619,243	-297,746	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-1.1%	27,347	27,650	28,410	26,991	29,244	40,864	41,991	13,409	2,203	2,502	1,817	1,858	1,045	551	139	64.00	98.00	146	109	1,247	1,147
Current Assets	-2.1%	24,890	25,435	26,099	24,947	27,312	40,861	41,989	13,405	2,196	2,492	1,804	1,842	1,026	528	112	34.00	66.00	110	71.00	231	1,101
Cash Equivalents	-13.6%	16,292	18,846	19,729	19,294	21,826	40,556	41,728	13,178	2,045	2,387	1,735	1,797	990	489	86.00	11.00	41.00	82.00	37.00	95.00	115
Inventory	27.0%	5,735	4,517	4,251	3,710	3,290	270	205	181	106	71.00	45.00	27.00	24.00	26.00	17.00	14.00	16.00	18.00	18.00	13.00	-
Net PPE	9.2%	366	335	367	368	394	4.00	2.00	4.00	7.00	10.00	13.00	17.00	20.00	23.00	26.00	30.00	32.00	36.00	39.00	254	45.00
Goodwill	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	666	666
Liabilities	8.0%	6,140	5,687	5,300	7,562	7,616	480	984	1,488	1,991	3,676	2,690	2,943	2,000	1,105	666	772	834	889	926	1,459	1,202
Current Liabilities	9.1%	5,552	5,088	4,660	6,906	6,931	480	105	95.00	91.00	472	636	865	1,051	748	603	772	834	889	926	1,120	912
Shareholder's Equity	-3.4%	21,207	21,963	23,110	19,429	21,628	40,384	41,886	13,314	212	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-2.0%	-63,905	-62,655	-62,004	-61,102	-59,399	-35,887	-34,430	-33,891	-32,655	-33,322	-29,282	-26,403	-20,218	-19,134	-18,436	-17,528	-17,434	-17,038	-16,687	-15,976	-15,774
Additional Paid-In Capital	0%	84,388	84,388	84,422	80,335	80,842	76,331	76,331	47,219	32,787	31,556	27,836	24,759	19,165	18,179	17,543	16,714	16,616	15,936	15,719	15,630	15,668
Accumulated Depreciation	-	190	-	-	-	84.00	-	69.00	67.00	64.00	61.00	58.00	55.00	51.00	47.00	44.00	40.00	37.00	33.00	30.00	75.00	23.00
Shares Outstanding	9.1%	280	257	257	221	226	189	97.00	71.00	26.00	23.00	24.00	22.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	10,708	-	-	-	19,950	-	-	-	62,198	-	-	-	2,790	-	-	-	3,714	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-488.2%	-2,689	-457	-3,778	-1,850	-2,246	-1,123	-573	-1,304	-312	-600	-618	-297	-423	-120	-82.02	-31.03	-127	-86.54	-47.46	-233	-116
Cashflow From Investing	-1527.6%	-269	19.00	-259	-146	-14,619	-	-	-	-	-	-	-	-391*	-800*	-	-	-860*	-1.44	-12.98	-	9.00
Cashflow From Financing	52.0%	-30.52	-63.57	4,058	-538	-2,096	-	29,124	12,438	-23.66	1,276	551	1,102	925	525	159	-	90.00	133	5.00	215	173
Buy Backs	-	-	-	-506	507	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

SBFM Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Sales	$ 24,092,787	$ 4,345,603
Cost of sales	15,753,616	2,649,028
Gross profit	8,339,171	1,696,575
General and Administrative Expenses:
Accounting	463,705	341,139
Consulting	850,173	842,894
Director fees	400,000	300,000
Goodwill impairment	0	18,326,719
Legal	512,199	550,117
Marketing	734,248	578,085
Office	2,142,355	796,007
Patent fees	14,108	15,148
R&D	1,855,830	811,858
Salaries	5,712,968	6,054,962
Taxes	289,737	55,233
Depreciation & amortization	149,147	25,163
Total General and Administrative Expenses	13,124,470	28,697,325
(Loss) From Operations	(4,785,299)	(27,000,750)
Other Income (Expense):
Foreign exchange (loss)	(245)	(476)
Interest income	811,974	518,650
Interest expense	(137,308)	(39,412)
Debt release	0	10,852
Total Other Income (Expense)	674,421	489,614
Net (loss) before income taxes	(4,110,878)	(26,511,136)
Provision for income taxes	395,166	233,304
Net (Loss	(4,506,044)	(26,744,440)
Foreign exchange translation	534,258	184,986
Comprehensive Income (Loss)	$ (3,971,786)	$ (26,559,454)

SBFM Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current Assets:
Cash and cash equivalents	$ 16,292,347	$ 21,826,437
Accounts receivable	2,552,362	1,912,153
Inventory	5,734,755	3,289,945
Prepaid expenses	310,591	283,799
Total Current Assets	24,890,055	27,312,334
Property and equipment	365,868	394,249
Intangible assets	1,444,259	776,856
Right-of-use-asset	646,779	760,409
TOTAL ASSETS	27,346,961	29,243,848
Current Liabilities:
Accounts payable and accrued expenses	2,585,466	2,802,797
Earnout payable	2,547,831	3,632,000
Income tax payable	299,869	373,191
Right-of-use-liability	118,670	123,026
Total Current Liabilities	5,551,836	6,931,014
Long-Term Liabilities:
Deferred tax liability	48,729	43,032
Right-of-use-liability	539,035	642,232
Total Long-Term Liabilities	587,764	685,264
TOTAL LIABILITIES	6,139,600	7,616,278
SHAREHOLDERS' EQUITY
Preferred Stock Series B $0.10 par value per share; 1,000,000 shares authorized 10,000 shares issued and outstanding	1,000	1,000
Common Stock $0.001 par value per share; 3,000,000,000 shares authorized 28,024,290 and 22,585,632 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	28,024	22,585
Capital paid in excess of par value	84,387,890	80,841,752
Accumulated comprehensive income	696,105	161,847
Accumulated (Deficit)	(63,905,658)	(59,399,614)
TOTAL SHAREHOLDERS' EQUITY	21,207,361	21,627,570
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 27,346,961	$ 29,243,848

About Sunshine Biopharma Inc.

Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; SBFM-PL4, an anti-coronavirus treatment compound; and K1.1 mRNA molecules used as anti-cancer agents. It also offers Essential 9, an amino acids capsules; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. Sunshine Biopharma, Inc. is based in Pointe-Claire, Canada.

CEO	Dr. Steve N. Slilaty Ph.D.
WEBSITE	https://sunshinebiopharma.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	46

Sunshine Biopharma Inc. Frequently Asked Questions

What is the ticker symbol for Sunshine Biopharma Inc.? What does SBFM stand for in stocks?

SBFM is the stock ticker symbol of Sunshine Biopharma Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Sunshine Biopharma Inc. (SBFM)?

As of Fri May 03 2024, market cap of Sunshine Biopharma Inc. is 835.4 Thousand. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SBFM stock?

You can check SBFM's fair value in chart for subscribers.

What is the fair value of SBFM stock?

You can check SBFM's fair value in chart for subscribers. The fair value of Sunshine Biopharma Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Sunshine Biopharma Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SBFM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Sunshine Biopharma Inc. a good stock to buy?

The fair value guage provides a quick view whether SBFM is over valued or under valued. Whether Sunshine Biopharma Inc. is cheap or expensive depends on the assumptions which impact Sunshine Biopharma Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SBFM.

What is Sunshine Biopharma Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 03 2024, SBFM's PE ratio (Price to Earnings) is -0.19 and Price to Sales (PS) ratio is 0.03. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SBFM PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Sunshine Biopharma Inc.'s stock?

In the past 10 years, Sunshine Biopharma Inc. has provided -0.757 (multiply by 100 for percentage) rate of return.